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INTRODUCTION
The pharmaceutical industry is facing a huge challenge in marketing new medicines mainly due to decreased R&D productivity and the decreasing number of truly innovative new medicines approved by the US Food and Drug Administration (FDA) (Booth and Zemmel, 2004) . For example, the number of new molecular entities (NMEs) that were approved by the FDA over 2000-2005 was 50% lower compared to the preceding 5 years.
Although big variation may exist between different classes of medicines, the average investment needed to bring a NME to the market is estimated to be approximately $1.8 billion and is still rising rapidly (Paul et al., 2010) . Interestingly, the number of drug candidates successfully reaching Phase 1 has increased over the past years, partly due to better preclinical characterization and improved ADMET properties. Nevertheless, attrition in latestage drug development (Phase II and III) is still high, and therefore remains the most important determinant of the overall R&D efficiency. For example, the Phase II success rates for NMEs have fallen from 28% (2006-2007) to 18% (2008) (2009) , while the prospect of successfully progressing through Phase II is currently 50%. Importantly, attrition in Phase II is mainly caused by insufficient efficacy of the newly developed drug, accounting for 51% of the drug failures (Arrowsmith, 2011; Arrowsmith, 2012; Kola and Landis, 2004) . The importance of correctly predicting the efficacy of novel drug candidates and demonstrating the disease-modifying potency of those candidates especially in the early stage pre-clinical phases is therefore crucial. While the translation from mouse to man proves to be difficult due to interspecies differences in efficacy and/or pharmacokinetics, humanized mouse models are being developed to improve such translation.
The ApoE*3Leiden (E3L) transgenic mouse model is a well-established humanized model for (familial) hyperlipidemia and cholesterol-induced atherosclerosis (van Vlijmen et al., 1994; Zadelaar et al., 2007) . E3L mice develop a human-like lipoprotein profile upon
5 feeding a fat and/or cholesterol-containing diet, with elevated plasma cholesterol and triglyceride levels mainly present in very-low-density lipoproteins (VLDL) and low-density lipoproteins (LDL). After long-term treatment (~14 weeks) with a fat and/or cholesterolcontaining diet, E3L mice develop atherosclerotic lesions with all the characteristics of human vascular pathology (Zadelaar et al., 2007) . The E3L mouse model is therefore a widely used model for studying the differential effects of cholesterol-lowering drugs (e.g.
statins, fibrates, niacin) (Kleemann et al., 2003; van Vlijmen et al., 1998; Verschuren et al., 2005; Verschuren et al., 2012; Zadelaar et al., 2007) .
Statins are lipid-lowering drugs that are widely prescribed to reduce the risk of primary and secondary of coronary heart disease. Statins reduce plasma cholesterol levels by inhibiting the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase and by enhancing hepatic uptake of LDL cholesterol via upregulation of LDL receptor expression (Liao and Laufs, 2005) . It is being estimated that about 50 million people take statins everyday worldwide. The currently marketed statins used in this study belong to the second (lovastatin, simvastatin and pravastatin) and third generation (atorvastatin and rosuvastatin) statins, with the latter having a higher affinity to inhibit HMG-CoA reductase and inhibit the enzyme for a longer duration (Kleemann and Kooistra, 2005) . This is also obvious from clinical studies that demonstrate that only atorvastatin and rosuvastatin can reduce plasma LDL-cholesterol by more than 40% in patients with hypercholesterolemia (Weng et al.,
6 reduce plasma cholesterol levels is largely dependent on the pharmacokinetics and local concentration of these drugs in the liver. For example, it has been demonstrated that patients carrying a variant of the hepatic uptake transporter, OATP1B1*15 (Asn130Asp and Val174Ala)which is known to have a strongly reduced transport activity, show markedly increased plasma levels, decreased pharmacological response and even increased extrahepatic toxicity after rosuvastatin or pravastatin treatment (Niemi et al., 2011) .
The aim of this study was to test the hypothesis that intelligent combination of pharmacokinetic and efficacy data may increase the predictability of drug efficacy outcomes in pre-clinical models. To this end, we setup a large scale preclinical study with E3L transgenic mice in which we determined the PK and efficacy profile of the 5 currently marketed statins, and compared them with their efficacy in humans based on data from a literature meta-analysis. Here, we report for the first time a systematic link between the hepatic uptake of statins and their cholesterol-lowering efficacy in a valuable mouse model of hyperlipidemia, and provide evidence that PK studies combined with efficacy studies could substantially improve the translational value of the E3L mouse model in case of statin treatment.
MATERIALS & METHODS

Systematic review of the cholesterol-lowering abilities of statins in humans
To systematically review the abilities of 5 commonly used statins (atorvastatin, pravastatin, simvastatin, lovastatin and rosuvastatin) known to reduce plasma cholesterol levels in patients with hyperlipidemia, we selected all clinical trials published between 1966
and 2009 that were previously also reviewed by Weng et al. and the Oregon Health Resources Commission (OHRC) (Beth Smith et al., 2009; Weng et al., 2010) . These meta-analyses used the following selection criteria to include the studies: (1) only randomized controlled trials with (2) head-to-head comparisons of at least two statins were included. Trials needed to be based on (3) human subjects older than 18 years, (4) that used statins as monotherapy to treat hyperlipidemia. The studies had to (5) report the primary data, (6) needed to last for at least 4 weeks, (7) and had to be published in English. As additional selection criteria, we only included trials in which patients with baseline plasma LDL-C levels of >160 mg/dL (i.e.
cutoff for hypercholesterolemia (National Cholesterol Education Program (NCEP), 2002))
were selected, resulting in 77 selected studies (see Supplemental data 1).
Animals
ApoE*3Leiden (E3L) mice, bred by The Netherlands Organization for Applied Scientific Research TNO, were housed and handled according to institutional guidelines complying with Dutch legislation. In this study we used female heterozygous E3L transgenic mice (8-12 weeks of age), characterized by enzyme-linked immunosorbent assay (ELISA) for the presence of human apoE*3 in the serum (van Vlijmen et al., 1998) . All animal experiments were approved by the Institutional Animal Care and Use Committee of TNO. .
Chemicals and reagents
The following drugs were supplemented to the diet: atorvastatin (Lipitor®; atorvastatin-calcium; Pfizer), pravastatin (Selektine®; pravastatin-sodium; Bristol-Myers 
Study design
During a 4-week week run-in period, all animals (except for the chow-control group, n=12) received a semi-synthetic high fat cholesterol (HFC) diet containing 40.5% sucrose, 15% cacao butter and 1% cholesterol (all w/w) (Abdiets, Woerden, The Netherlands #4021.04). After randomization into 11 groups (n=8 per group) matched for age, body weight, plasma cholesterol and triglyceride levels, the mice received HFC diet alone (control group) or HFC supplemented with either atorvastatin (0.003% or 0.008% w/w), pravastatin
Analysis of plasma lipids
Blood was sampled after 4 hours of fasting into EDTA-containing cups by tail bleeding, and plasma was isolated. Immediately after isolation, total plasma cholesterol (TC) and total plasma triglyceride (TG) levels were measured with commercially available enzymatic kits according to manufacturer's protocols (Roche Diagnostics, No-1489437 for total cholesterol; Roche Diagnostics, No-1488872 for triglyceride).
Plasma and tissue pharmacokinetic experiments
The groups of mice that were treated with the highest dose of statin were used for analysis of pharmacokinetics. The evening prior to the PK study, diets of all mice were switched to the HFC control diet, to allow washout of the statin (t 1/2 of orally dosed statins ≤ 5 hours in mice (Iusuf et al., 2012; Lau et al., 2006; Peng et al., 2009; Tiwari and Pathak, 2011; Zhu et al., 2011) ). Subsequently, after 2-hours of fasting, mice were dosed with 10 mg/kg of the different statins (10 µL drug solution/g body weight; 1 mg/mL in saline finally containing 8.3% EtOH:polysorbate 80 (1:1, v/v)) by oral gavage. In case of [
Drug analysis Simvastatin in plasma and liver were determined by HPLC and LC-MS analysis, respectively (see below).
HPLC analysis of lovastatin and simvastatin
Levels of lovastatin acid and simvastatin acid in plasma and liver were measured by HPLC analysis based on the method previously described by Zhang et al. (Zhang and Yang, 2007) . In brief, 50 µL methanol and 200 µL acetonitrile were added to 100 µL of plasma or liver homogenate (homogenized in ice-cold saline using a Ultra-turrax). After thoroughly vortexing, the samples were centrifuged for 10 minutes (14,000 rpm at room temperature), and 20 µL of the supernatant was injected into the column (Hypersil BDS column; 250 x 4.6 mm, 5 µm) for analysis. Samples were eluted at flow rate of 1.0 mL/minute at 20ºC with 0.1% trifluoroacetic acid in water (solvent A) and 0.1% trifluoroacetic acid in acetonitrile (solvent B). The following mobile phase conditions were used: 0-10 min linear from 100% to 60 % A and 0% to 40% B; 10-30 min linear from 60% to 30% A and 40% to 70% B; 30-40 min linear from 30% to 0% A and 70% to 100% B; 35-40 min 100% B (isocratic). UVchromatograms were obtained at 238 nm. Peak identification and quantification was performed using Lablogic Laura software.
UPLC-MS analysis of simvastatin
Fractions of the livers (~200 mg) were sonificated twice in acetonitrile. Lysates were centrifuged 10 minutes at 14,000 rpm and 5 µL of the supernatant was injected into the 
Data and statistical analysis
ED 30 values of statin efficacy in human and mouse were determined by linear regression with a 95% confidence interval (CI) (Liengme, 2010) . Unless otherwise specified, the two-sided unpaired Student's t-test was used throughout the study to assess the statistical significance of differences between two sets of data. Differences were considered to be statistically significant when p < 0.05.
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RESULTS
Comparison of cholesterol-lowering effects of statins in humans
The cholesterol-lowering effects of the different statins in patients with hypercholesterolemia are shown in Figure 1 and Supplemental data 1. There was a clear linear dose-effect relation, with exception for atorvastatin and rosuvastatin at the highest dose of 80 mg/day, which might be due to saturation of HMG-CoA reductase inhibition (Supplemental data 2). We also observed a clear and significant correlation between the reduction in plasma levels of TC and LDL-C after statin treatment (R 2 0.83, p<0.001; data not shown 
Comparison of lipid-lowering effects of statins in E3L mice
E3L mice treated with a HFC diet containing 1% cholesterol for 4 weeks showed on average a 5.3-fold increase in plasma total cholesterol levels compared to the chow-control reference mice. After this 4-week run-in period to achieve steady state conditions, mice were randomized into 11 groups (n=8 per group) based on age, body weight, plasma cholesterol and triglyceride levels, and received the HFC diet (control group) or supplemented with different doses of statin during an intervention period of 6 weeks ( Table 1) . Body weights and food intake of the E3L mice during the intervention period are presented in Table 1 and 13 except the group receiving 1.26 mg/day lovastatin of which the food intake was 2.5 g/day (p < 0.05; one-way ANOVA followed by Dunett's multiple comparison test; Table 1 ). The average food intake in the chow-control group was 3.7 g/day. The effects of the different statins on plasma TC levels after 6 weeks of treatment in E3L mice are presented in Table 2 (individual data in Supplemental data 3). Except for simvastatin, all statins decreased plasma TC levels by at least 30% at the highest tested dose tested. Based on the food intake we calculated the statin intake (mg/day) per group and plotted these against the percentage reduction in TC compared to the HFC-control group (Figure 3 (Figure 3 ). The effects of the different statins on plasma TG levels after 6 weeks of treatment in E3L mice are presented in Table 2 (individual data are presented in Supplemental data 4). Rosuvastatin, pravastatin and lovastatin decreased plasma TG levels in E3L mice (62%, 63% and 59% upon treatment of E3L mice with 0.13 mg rosuvastatin/day, 1.02 mg pravastatin/day and 1.77 mg lovastatin/day, respectively), as has been observed before (Delsing et al., 2005; Kleemann et al., 2003; van der Hoorn et al., 2007) . Atorvastatin and simvastatin, however, did not statistically change plasma TG levels in E3L mice, which is also in agreement with previous observations (Delsing et al., 2003; van et al., 2001; Wang et al., 2002) .
Pharmacokinetic analysis of different statins in E3L mice
This article has not been copyedited and formatted. The final version may differ from this version. To study putative differences in pharmacokinetics and tissue distribution between the various statins used in this study, E3L mice were orally dosed with a bolus injection of 10 mg/kg of the (radiolabelled) drug. Concentrations of the statin in plasma and liver are presented in Figure 4 and Figure 5 , respectively. Plasma exposure as determined by the AUC was 373 min·µg/mL (pravastatin), 101 min·µg/mL (simvastatin), 36.6 min·µg/mL (atorvastatin), 9.77 min·µg/mL (rosuvastatin) and 4.78 min·µg/mL (lovastatin). Interestingly, liver levels did not correlate with the plasma levels of the different statins, and were from high to low 14.7 (atorvastatin), 9.81 (pravastatin), 4.58 (rosuvastatin), 3.49 (lovastatin) and 1.56 (simvastatin) µg/g 30 minutes after administration. Liver-to-plasma ratios of the individual statins 30 and 120 minutes after oral administration are presented in intestine (tissue plus contents), colon (tissue plus contents) and kidney as well (Supplemental data 5). Drug levels in the stomach were comparable between the three statins (~50 µg/g 30 minutes after dosage). Compared with rosuvastatin and atorvastatin, pravastatin showed the lowest level of drug in the small intestine (including contents), concomitantly with the highest plasma AUC and highest level of drug present in the kidneys. These data suggest that pravastatin has the highest oral bioavailability of these statins in E3L mice.
Comparison of the efficacy of different statins between humans and E3L mice
The cholesterol-lowering efficacy of the different statins used in this study was compared between humans and E3L mice. between the statins in mice (Figure 6 ). Importantly, after correcting for the average liver concentrations in E3L mice, we found a significant correlation between the efficacy of statins in humans and E3L mice (R 2 0.89, p<0.05; Figure 6C ). The hepatic extraction of statins in humans is 80% for simvastatin, 70% for atorvastatin and lovastatin, 65% for rosuvastatin and 45% for pravastatin (Neuvonen et al., 2006) . When correspondingly taking these differences into account, the correlation between human and mouse studies was even further increased (R 2 0.99, p<0.001; Figure 6D ).
This article has not been copyedited and formatted. The final version may differ from this version. 
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DISCUSSION
The E3L transgenic mouse model exhibits a human-like plasma lipid profile in response to high fat diet feeding and develops atherosclerotic lesions that resemble their human counterparts (van Vlijmen et al., 1994; Verschuren et al., 2012; Zadelaar et al., 2007 ).
This mouse model is a valid and still widely used mouse model for studying the cholesterollowering and pleiotropic effects of (newly developed) drugs (e.g. statins, fibrates, ezetimibe, olmesartan). There is currently a required focus of the pharmaceutical industry to correctly predict the efficacy of novel drug candidates in early stage pre-clinical phases. We therefore aimed to map the predictive value of the E3L mouse model regarding the cholesterollowering efficacy of a set of statins. Importantly, since the pharmacokinetics and especially the concentration at the target site co-determines the efficacy of drugs, we hypothesized that combining pharmacokinetic with efficacy data can increase the predictability of drug efficacy in pre-clinical models. To this end, the efficacy profile of 5 currently marketed statins was determined in E3L transgenic mice, and compared with their efficacy in humans based on data obtained from a comprehensive meta-analysis of human trials. Besides efficacy, we also determined the pharmacokinetics and tissue distribution of these drugs in E3L mice. These results show that oral bioavailability and target organ concentrations varied markedly between the statins. We demonstrate that consideration of these differences improves the prediction of the efficacy of the drugs in preclinical model and facilitates the translation of preclinical data to situation in humans.
Statins are being widely prescribed to reduce circulating cholesterol levels and lower the risk of cardiovascular events for more than 2 decades now. The various effects of atorvastatin, rosuvastatin and pravastatin have previously been studied in E3L transgenic mice (Delsing et al., 2003; Delsing et al., 2005; Kleemann et al., 2003; van de Poll et al., 2003; van der Hoorn et al., 2007; Verschuren et al., 2005) . These studies revealed that E3L
This article has not been copyedited and formatted. The final version may differ from this version. mice, unlike other mouse models of CVD, respond to these hypolipideamic drugs by a reduction plasma cholesterol levels, and that statins can reduce atherosclerotic plaque formation in these mice, partly even beyond and independent of the cholesterol-lowering effect. This latter effect might be explained by the more pleiotropic effects of statin drugs (e.g. anti-inflammatory effects) in the vasculature and the liver, and is in line with observations in humans (Liao and Laufs, 2005 ). In the current study we concentrated on the cholesterol-lowering effects of the statins in the preclinical E3L model. The observed ED 30 values of atorvastatin and rosuvastatin (0.14 and 0.11 mg/day, respectively) in this study are highly comparable to those found in studies by Verschuren et al (atorvastatin: ~0.13 mg/day) and Delsing et al (rosuvastatin: ~0.09 mg/day) that were carried out more than 7 years ago using the same mouse model and comparable dietary conditions (Delsing et al., 2005; Verschuren et al., 2005) . This clearly demonstrates the validity and reproducibility of the E3L transgenic mouse model for these type of research questions.
We determined plasma exposure and liver uptake of the different statins in E3L mice that were exposed to statin therapy for 6 weeks after an oral bolus injection of 10 mg/kg. It has been shown before that rosuvastatin is more efficiently taken up by hepatic cells than pravastatin and simvastatin (Nezasa et al., 2002) . Here, we also observed more than 30-fold increased liver-to-plasma ratio of rosuvastatin compared to simvastatin and pravastatin, albeit 18 bioavailability (i.e. plasma exposure after oral administration) of pravastatin in mice compared to the other statin drugs. To the best of our knowledge, this has never been published before. Notably, this finding is substantiated by the relative low levels of remaining pravastatin in the small intestine and colon 30 and 120 minutes after dosing (Supplemental data 5). The high plasma exposure, but more importantly the relatively high liver uptake of pravastatin in E3L mice, might explain the rather high cholesterol-lowering efficacy of pravastatin compared to the other 2 second generation statins, lovastatin and atorvastatin. In contrast, simvastatin, which also has a rather high plasma exposure (101 min·µg/mL) in E3L
mice, but the lowest hepatic uptake, was the least effective. These results for the first time 
19
Only after taking into account the differences in liver uptake of these statins in E3L mice, we found a significant correlation between the cholesterol-lowering efficacy of these statins in E3L mice and patients with hypercholesterolemia. The fact that just correcting for differences in liver accumulation of the various statins in E3L mice is already sufficient to gain a good correlation, suggests that the relative differences in liver uptake between these statins in humans are minor compared to E3L mice. Hepatic extraction of simvastatin, lovastatin, atorvastatin and rosuvastatin is reported to be comparable in humans (65-80%), whereas that of pravastatin is slightly lower (45%) (Neuvonen et al., 2006; Neuvonen et al., 2008) . When taking into account these minor differences in hepatic extraction of the studied statins, we retrieve an even better correlation between the efficacy of the drugs in humans and E3L mice ( Figure 6D ).
In conclusion, in this study we provide evidence that a combined PK-efficacy study substantially improves the translational value of the E3L mouse model in case of the cholesterol-lowering effect of statin treatment. We hypothesize that a similar strategy could be used to increase the clinical predictability of drug treatment of other classes of drugs in various pre-clinical (disease) models.
This article has not been copyedited and formatted. The final version may differ from this version. Contributed to the writing of the manuscript: Steeg, Kleemann, Wortelboer, DeGroot Data are presented as means ± SD, n=4 na, not applicable (plasma levels were < lower limit of quantification; LLQ)
